869186-74-3Relevant academic research and scientific papers
BCL-2 INHIBITORS AND THEIR USE AS PHARMACEUTICALS
-
Paragraph 0505; 0508-0509, (2021/11/13)
The disclosure is directed to, in part, to BCL-2 inhibitors, pharmaceutical compositions comprising the same, as well as methods of their use and preparation.
NOVEL COMPOUNDS
-
Page/Page column 130, (2014/10/03)
The present invention relates substituted N-biphenyl-3-acetylamino-benzamides and N-[3-(acetylamino)phenyl]-biphenyl-carboxamides of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative disorder, as a sole agent or in combination with other active ingredients.
NOVEL COMPOUNDS
-
Page/Page column 135, (2014/10/03)
The present invention relates to substituted N-(phenyl-heteroaryl)-3-acetylamino-benzamides and N- [3-(acetylamino)phenyl]-phenyl-heteroaryl-carboxamides of general formula(I) as described and defined herein,to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease.
SULFONAMIDE DERIVATIVES FOR THERAPEUTIC USE AS FATTY ACID SYNTHASE INHIBITORS
-
Page/Page column 169-170, (2008/12/06)
A compound of formula (I) or a pharmaceutically acceptable salt thereof, processes for preparing such compounds, their use as Fatty Acid Synthase inhibitors, methods for their therapeutic use, particularly in the treatment of obesity and diabetes mellitus
